Pharmaceutical composition using albumin as a carrier and process for producing the same

• US 5,051,406 A
• Filed: 11/30/1990
• Issued: 09/24/1991
• Est. Priority Date: 03/04/1987
• Status: Expired due to Fees

• Current Assignee: Fuji Yakuhin Company Limited
• Original Assignee: Nippon Hypox Laboratories Incorporated
• Inventors: Satoh, Toshio
• Primary Examiner(s): Schain, Howard E.
• Assistant Examiner(s): KOH, CHOON P
• Application Number:
  US07/620,394
• Time in Patent Office: 298 Days
• Field of Search: 514/776, 514/21, 530/362, 530/363
• US Class Current: 514/2.4
• CPC Class Codes: A61K 47/42 Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein oligopeptides having up to five amino acids A61K47/183; polyamino acids A61K47/34
• CPC Class Codes: A61K 47/643 Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
• CPC Class Codes: A61K 9/146 with organic macromolecular compounds

Abstract

The pharmaceutical composition of the present invention is a pharmaceutical composition of high drug content containing 1-200 parts by weight of a drug having a protein binding property and 100 parts by weight of albumin.

This pharmaceutical composition is produced by stirring the drug and albumin of the above proportions at a high speed in an aqueous solvent and then removing the solvent by distillation, and has effects of alleviating the side effect of the drug used therein and also of improving the absorption, light stability, etc. of the drug.

Claims

1. A process for producing a pharmaceutical composition comprising mixing together at high speed in a solvent 1 to 250 parts by weight of a drug capable of binding to protein and 100 parts by weight of albumin, and thereafter

(2) removing the solvent, wherein the drug is nifedipine, aspirin, nalidixic acid, piroxicam, sulindac, phenylbutazone, cefaclor, cefalexin, tetracycline hydrochloride, ampicillin, dexamethasone, dlα

-tocopherol, haloperidol, diltazem hydrochloride, defalexin, griseofulvin, vincristine sulfate, cimetidine, ketotifen, glycyrrhizin or tranilast.

2. A process according to claim 1, wherein the amount of the drug is 5-200 parts by weight.

3. A process according to claim 1, which further uses a fatty oil and/or a fatty acid.

4. A process according to claim 1, wherein the aqueous solvent is water or a mixture of water and an organic solvent.

5. A process according to claim 3, wherein the drug is dissolved in the fatty oil and/or the fatty acid in the presence of an organic solvent if necessary and then the resulting solution is added to an aqueous suspension of natural albumin.

6. A process according to claim 1, wherein the stirring is effected at a high speed of 5,000-40,000 rpm.